GleamWall
中文EN

LKFT Lakefront Biotherapeutics NV IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1421876 · Reporting currency EUR

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY303.5%
TTM net income YoY333.1%
TTM EPS YoY334.8%
Revenue 3-yr CAGR66.4%
Net income 3-yr CAGR—

Margins

Gross margin97.3%
Operating margin26.5%
Net margin28.9%
FCF margin-24.4%
EBITDA margin—

Returns

ROE10.5%
ROA8.5%
ROIC (approx.)9.9%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets5.0%
Debt / equity0.00x
Current ratio20.15x
Interest coverage285.34x

Cash quality & payout

Operating cash flow / net income-0.80x
Accruals ratio15.3%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY20252025-12-31FY20242024-12-31
Income statement
Revenue1.11B275.65M
Cost of revenue29.74M34.86M
Gross profit1.08B240.79M
R&D expense459.42M335.46M
SG&A expense147.33M117.25M
Operating income295.04M-188.34M
Interest expense1.03M911,000
Pretax income300.87M-3.08M
Income tax-18.62M-1.80M
Net income320.88M74.08M
EPS (basic)4.871.12
EPS (diluted)4.871.12
Weighted avg. shares (diluted)65.90M65.90M
Balance sheet
Cash & equivalents87.87M64.24M
Short-term investments2.91B3.05B
Receivables20.71M47.48M
Inventory22.49M51.19M
Current assets3.08B3.34B
PP&E, netmay include right-of-use assets (IFRS)71.95M105.40M
Goodwill—70.01M
Intangibles848,000164.86M
Total assets3.41B4.14B
Current liabilities152.86M335.08M
Total liabilities170.65M1.24B
Shareholders' equity3.24B2.90B
Cash flow statement
Operating cash flow-257.46M-320.03M
Capital expenditure13.70M16.72M
Free cash flow-271.16M-336.75M
Investing cash flow288.81M220.60M
Financing cash flow-3.27M-4.92M
Stock-based compensation24.00M19.89M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.